Compare IDEXX Laboratories, Inc. (IDXX) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Medtronic PLC — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Medtronic PLC trades at $88.79 (market cap $112.24B). The key difference: Medtronic PLC is far larger — about 2.8× IDEXX Laboratories, Inc.'s market cap, and Medtronic PLC pays a 3.28% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Medtronic PLC for 63 Days on average.
| IDXX | MDT | |
|---|---|---|
Market Cap | $40.43B | $112.24B |
Volume | 692,164 | 105,663,236 |
Sector | Health | Health |
52-Week High | $766.68 | $105.35 |
52-Week Low | $504.70 | $73.75 |
Typical Hold Time | 46 Days | 63 Days |
Enterprise Value | $41.32B | $131.58B |
Dividend Yield | — | 3.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
Medtronic (MDT) trades at $88.48, up 3.47% today, with a bullish analyst consensus and a $97.80 price target. The stock shows strong fundamentals with revenue growth to $33.54B in 2025 and a net income margin of 13.93%. Recent earnings beats and a 49-year dividend growth streak highlight operational strength, though technical indicators signal a near-term bearish trend with key support at $87.
MDT presents a compelling long-term investment with stable profitability and dividend reliability, but faces risks from debt increases and competitive pressures. Upside potential exists if the company maintains earnings momentum and executes on growth initiatives, while volatility may persist due to market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
